en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2024
vol. 99
 
Share:
Send email
Share:
abstract:
Review paper

A genetic disease under the multiform mask – infantile-onset of Pompe disease

Klaudia Jadczak
1
,
Anna Kadłubiska
2
,
Kornel Semeran
2
,
Artur Bossowski
2

  1. Student Scientific Circle at the Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
  2. Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
Pediatr Pol 2024; 99 (3): 218-224
DOI: https://doi.org/10.5114/polp.2024.143087
Online publish date: 2024/09/19
View full text Get citation
 
PlumX metrics:
Acid α-glucosidase deficiency – Pompe disease (PD) is a genetic, autosomal recessively inherited disorder leading to impaired glycogen degradation and storage in cells, especially muscles. It occurs with a frequency of 1 : 10,000 – 1 : 40,000 live births. This article presents a currently 14-year-old girl diagnosed with infantile-onset PD. A 15 days old the girl was referred to the hospital due to tachycardia. On examination, reduced muscle tone and hepatomegaly were observed. Electrocardiography showed supraventricular tachycardia. Laboratory tests detected increased hepatic aminotransferase activity. Echocardiography of the heart showed features of hypertrophy of both chambers. The patient was referred to the Children’s Memorial Health Institute in Warsaw. Pompe disease was diagnosed. At 4 months of age, therapy with Myozyme, administered intravenously every other week, was started, and it continues to the present day. Early recognition of PD and initiation of substitution therapy allow its course to be slowed and patients’ lives to be extended.
keywords:

disease, glycogen, α-glucosidase, Myozyme